MR-1050

N/A

Report date: 2025/06/11 10:53:04
NME

Base Information

Drug NameMR-1050
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionAnticancer protein kinase inhibitorsCyclin-dependent kinase 12 inhibitors
TargetsCyclin-dependent kinase 12
Therapy Area/IndicationsTriple Negative Breast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesH Lee Moffitt Cancer Center & Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesH Lee Moffitt Cancer Center & Research Institute
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A